Literature DB >> 24168783

An increase of VEGF plasma levels is associated with restenosis of drug-eluting stents.

Katharina M Katsaros1, Stefan P Kastl, Konstantin A Krychtiuk, Randolph Hutter, Gerlinde Zorn, Gerald Maurer, Kurt Huber, Johann Wojta, Günter Christ, Walter S Speidl.   

Abstract

AIMS: Drug-eluting stents (DES) reduce late lumen loss compared to bare metal stents but were not able to eradicate in-stent restenosis (ISR) fully. Vascular endothelial growth factor (VEGF) may inhibit late lumen loss through accelerated reendothelialisation, but may also promote neointima formation by proinflammatory effects. The aim of this study was to evaluate whether endogenous plasma levels of VEGF are associated with development of ISR after implantation of DES. METHODS AND
RESULTS: We studied 85 patients who were treated with 159 DES. VEGF plasma levels were determined before and 24 hours after PCI. During the eight-month follow-up period, two patients (2.4%) died of cardiovascular causes and 12 patients (14.5% of patients, 7.6% of stents) developed angiographic ISR. Basal VEGF plasma levels were not different in patients with and without ISR at follow-up. In contrast to patients without ISR, VEGF increased significantly upon PCI in patients with ISR (p<0.005). Patients with a decrease of VEGF after PCI had a restenosis rate of 2.4% compared to a restenosis rate of 26.2% in patients with an increase of VEGF after the procedure (p<0.05). This was independent from clinical and angiographic risk factors.
CONCLUSIONS: Basal plasma levels of VEGF are not associated with the development of ISR. However, an increase of VEGF after PCI is associated with a dramatically increased ISR rate after implantation of DES.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24168783     DOI: 10.4244/EIJV10I2A36

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  5 in total

1.  TLR3 and TLR4 as potential clinical biomarkers for in-stent restenosis in drug-eluting stents patients.

Authors:  Shao Liang; Ma Aiqun; Li Jiwu; Zhang Ping
Journal:  Immunol Res       Date:  2016-04       Impact factor: 2.829

2.  Association of the Endothelial Nitric Oxide Synthase Gene T786C Polymorphism with In-Stent Restenosis in Chinese Han Patients with Coronary Artery Disease Treated with Drug-Eluting Stent.

Authors:  Wen-Ping Zeng; Rui Zhang; Ran Li; Jin-Fang Luo; Xiao-Feng Hu
Journal:  PLoS One       Date:  2017-01-27       Impact factor: 3.240

3.  Association between VEGF Gene Polymorphisms and In-Stent Restenosis after Coronary Intervention Treated with Bare Metal Stent.

Authors:  Zsolt Bagyura; Loretta Kiss; Kristóf Hirschberg; Balázs Berta; Gábor Széplaki; Árpád Lux; Zsolt Szelid; Pál Soós; Béla Merkely
Journal:  Dis Markers       Date:  2017-03-07       Impact factor: 3.434

4.  Inverse Relationship between Serum VEGF Levels and Late In-Stent Restenosis of Drug-Eluting Stents.

Authors:  Jiasheng Yin; Li Shen; Meng Ji; Yizhe Wu; Sishi Cai; Jiahui Chen; Zhifeng Yao; Junbo Ge
Journal:  Biomed Res Int       Date:  2017-03-08       Impact factor: 3.411

5.  The Relationships between Polymorphisms in Genes Encoding the Growth Factors TGF-β1, PDGFB, EGF, bFGF and VEGF-A and the Restenosis Process in Patients with Stable Coronary Artery Disease Treated with Bare Metal Stent.

Authors:  Tadeusz Osadnik; Joanna Katarzyna Strzelczyk; Rafał Reguła; Kamil Bujak; Martyna Fronczek; Małgorzata Gonera; Marcin Gawlita; Jarosław Wasilewski; Andrzej Lekston; Anna Kurek; Marek Gierlotka; Przemysław Trzeciak; Michał Hawranek; Zofia Ostrowska; Andrzej Wiczkowski; Lech Poloński; Mariusz Gąsior
Journal:  PLoS One       Date:  2016-03-01       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.